Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials

Various novel androgen receptor (AR) targeting drugs have been developed recently and have shown beneficial effects on survival in patients with metastatic castration-resistant prostate cancer (mCRPC). However, no consensus has been reached regarding which of these agents provides the most favorable...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Oncotarget
Egile Nagusiak: Kang, Minyong, Jeong, Chang Wook, Kwak, Cheol, Ku, Ja Hyeon, Kim, Hyeon Hoe
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Impact Journals LLC 2017
Gaiak:
Meta-Analysis
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5601768/
https://ncbi.nlm.nih.gov/pubmed/28938672
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17741
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak